ACS Chemical Neuroscience
May 12, 2020
Kodye L. Abbott, Kristina Gill, Patrick Flannery et al.
7 citations
Regulations intended to prevent harm and addiction from substances like cannabis, MDMA, LSD, and psilocybin also create major barriers for scientists trying to study these drugs. The authors argue that modifying current drug scheduling to reclassify illicit substances would allow extensive testing in research settings, potentially advancing life-saving research.
Trends in Medical Research
June 28, 2024
Bennett Lange, Luke Morgan, Christopher Mattox et al.
Psilocybin, the psychedelic compound in magic mushrooms, is converted in the liver to psilocin, which acts as a 5-HT2A agonist and affects multiple human organ systems including the central nervous, cardiovascular, digestive, and immune systems. This review examines the historical, current, and future uses of magic mushrooms in healthcare, covering nutraceutical, prophylactic, and therapeutic pathways, as well as toxicological effects on these organ systems and their danger levels.
July 15, 2021
Julia M. Salamat, Kodye L. Abbott, Patrick Flannery et al.
This chapter reviews psychoactive illicit substances of fungal origin, focusing on psilocybin, the hallucinogenic compound in 'magic mushrooms' from genera such as Conocybe, Gymnopilus, Panaeolus, Pluteus, and Psilocybe. It describes neurological and related adverse events that can result from pharmacokinetic interactions between these fungal substances and clinical drugs in humans. The chapter also outlines directions for future research to better understand the underlying mechanisms of these adverse events.